Target intelligence / Profile preview

Acyl carrier protein (ACP)

Target
ACP
Molecular classification
Carrier protein, Cofactor protein, Other
01

Overview

Acyl carrier protein (ACP) is a small, highly conserved protein that acts as a central scaffold in the biosynthesis of fatty acids and related secondary metabolites, such as polyketides. ACP carries growing acyl chains covalently via a thioester bond to a 4'-phosphopantetheine prosthetic group attached to a conserved serine residue. This transfer and delivery function is essential for the stepwise elongation of fatty acids and assembly of complex natural products. In bacteria and plastids, ACP exists as an independent protein (Type II FAS); in eukaryotic cytosol, ACP is a domain of the large multifunctional Type I fatty acid synthase complex. The structure is a four-helix bundle with conformational flexibility, crucial for its function as an interaction hub for biosynthetic enzymes. Due to its essential role in bacterial viability and secondary metabolism, ACP and its associated pathways are considered attractive targets for new antibiotics and anticancer agents[1][3][5][6].

Other names
Peptidyl carrier protein (historically related but distinct)ACP (common abbreviation)sometimes "Fatty acid synthase ACP domain" (in eukaryotes)mitochondrial acyl carrier protein (in mitochondria)
02

Mechanism of action

Inhibition of ACP or ACP-dependent enzymes may block fatty acid biosynthesis in bacteria, inhibiting cell growth and survival[5][7]. Small molecules may disrupt the interaction between ACP and partner enzymes.

03

Biological functions

Fatty acid biosynthesisPolyketide biosynthesisSecondary metabolite productionAcyl group transport
04

Disease associations

Infection (ACP is essential in many pathogenic bacteria, making it a potential antimicrobial target)[5]Other (Its essentiality in primary metabolism of bacteria links it to cell growth and pathogen survival[5][7])
05

Safety considerations

As ACP is highly conserved in bacteria, plants, and mitochondria of eukaryotes, selective toxicity is a challenge—off-target effects on human or plant fatty acid biosynthesis are safety concerns in drug development[5][7]Essentiality to cell metabolism raises risk of toxicity if not targeted specifically in pathogens
06

Interacting drugs

Experimental antimicrobial compounds targeting ACP-dependent enzymes or ACP itself[5][7]

1 more in the full profile.

07

Biomarkers

Null (no established clinical biomarkers based on ACP status)

Beyond the preview

Go deeper on Acyl carrier protein (ACP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acyl carrier protein (ACP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call